Header Logo

Connection

Priyabrata Mukherjee to Animals

Back to Details
This is a "connection" page, showing publications Priyabrata Mukherjee has written about Animals.
Priyabrata Mukherjee
Connection Strength
0.945
Animals
  1. Hydrogen sulfide signaling in mitochondria and disease. FASEB J. 2019 12; 33(12):13098-13125.
    View in: PubMed
    Score: 0.063
  2. Nanoparticle Interactions with the Tumor Microenvironment. Bioconjug Chem. 2019 09 18; 30(9):2247-2263.
    View in: PubMed
    Score: 0.062
  3. Probing Cellular Processes Using Engineered Nanoparticles. Bioconjug Chem. 2018 06 20; 29(6):1793-1808.
    View in: PubMed
    Score: 0.057
  4. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.053
  5. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget. 2015 Nov 10; 6(35):37367-84.
    View in: PubMed
    Score: 0.048
  6. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Aug 15; 5(15):6453-65.
    View in: PubMed
    Score: 0.044
  7. Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component. Sci Rep. 2014 Jul 11; 4:5669.
    View in: PubMed
    Score: 0.043
  8. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.
    View in: PubMed
    Score: 0.041
  9. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One. 2013; 8(3):e57522.
    View in: PubMed
    Score: 0.040
  10. Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem. 2011 Dec; 11(10):965-73.
    View in: PubMed
    Score: 0.036
  11. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011; 6(9):e24374.
    View in: PubMed
    Score: 0.036
  12. A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity. Chem Commun (Camb). 2011 Aug 14; 47(30):8530-2.
    View in: PubMed
    Score: 0.035
  13. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One. 2011; 6(6):e20347.
    View in: PubMed
    Score: 0.035
  14. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011 Feb; 28(2):237-59.
    View in: PubMed
    Score: 0.034
  15. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010 Mar 08; 62(3):346-61.
    View in: PubMed
    Score: 0.031
  16. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7659-66.
    View in: PubMed
    Score: 0.029
  17. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev. 2008 Aug 17; 60(11):1289-1306.
    View in: PubMed
    Score: 0.028
  18. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005 May 01; 11(9):3530-4.
    View in: PubMed
    Score: 0.023
  19. Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury. Mayo Clin Proc. 2022 01; 97(1):154-164.
    View in: PubMed
    Score: 0.018
  20. Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer. Acta Biomater. 2022 01 15; 138:453-462.
    View in: PubMed
    Score: 0.018
  21. Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. ACS Appl Mater Interfaces. 2021 Oct 27; 13(42):49614-49630.
    View in: PubMed
    Score: 0.018
  22. Improved pentamethine cyanine nanosensors for optoacoustic imaging of pancreatic cancer. Sci Rep. 2021 02 23; 11(1):4366.
    View in: PubMed
    Score: 0.017
  23. Cystathione ß-synthase regulates HIF-1a stability through persulfidation of PHD2. Sci Adv. 2020 07; 6(27).
    View in: PubMed
    Score: 0.016
  24. On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol. 2019 07; 14(7):629-635.
    View in: PubMed
    Score: 0.015
  25. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther. 2018 10; 17(10):2136-2143.
    View in: PubMed
    Score: 0.014
  26. LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res. 2018 04 15; 78(8):1923-1934.
    View in: PubMed
    Score: 0.014
  27. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.
    View in: PubMed
    Score: 0.014
  28. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget. 2016 Nov 08; 7(45):72845-72859.
    View in: PubMed
    Score: 0.013
  29. Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB J. 2016 12; 30(12):4042-4055.
    View in: PubMed
    Score: 0.013
  30. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.012
  31. Neuroprotectin D1 is synthesized in the cone photoreceptor cell line 661W and elicits protection against light-induced stress. Cell Mol Neurobiol. 2015 Mar; 35(2):197-204.
    View in: PubMed
    Score: 0.011
  32. Sonochemically prepared BSA microspheres containing Gemcitabine, and their potential application in renal cancer therapeutics. Acta Biomater. 2009 Oct; 5(8):3031-7.
    View in: PubMed
    Score: 0.008
  33. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem. 2005 Aug 12; 280(32):28848-51.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.